{
    "Trade/Device Name(s)": [
        "GlucoLeader Enhance Blood Glucose Monitoring System"
    ],
    "Submitter Information": "HMD BioMedical, Inc.",
    "510(k) Number": "K182428",
    "Predicate Device Reference 510(k) Number(s)": [
        "K032985"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NBW"
    ],
    "Summary Letter Date": "March 31, 2019",
    "Summary Letter Received Date": "April 8, 2019",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 862.1345"
    ],
    "Regulation Name(s)": [
        "Glucose test system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Fresh capillary whole blood (fingertip)"
    ],
    "Specimen Container(s)": [
        "Test strip"
    ],
    "Instrument(s)/Platform(s)": [
        "GlucoLeader Enhance Blood Glucose Meter"
    ],
    "Method(s)/Technology(ies)": [
        "Amperometry glucose biosensor",
        "Glucose dehydrogenase-FAD enzyme"
    ],
    "Methodologies": [
        "Quantitative measurement"
    ],
    "Submission Type(s)": [
        "System",
        "Meter",
        "Test Strip",
        "Control Solution",
        "Check Strip"
    ],
    "Document Summary": "FDA 510(k) summary for GlucoLeader Enhance Blood Glucose Monitoring System using amperometric biosensor for quantitative glucose measurement in capillary whole blood.",
    "Indications for Use Summary": "Intended for quantitative measurement of glucose in fresh capillary whole blood from the fingertip for self-testing by people with diabetes at home as an aid to monitor effectiveness of diabetes control; not for diagnosis or screening for diabetes and not for use in neonates.",
    "fda_folder": "Clinical Chemistry"
}